Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.67 |
| ▸ | ARG1 | P05089 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28043028 | 0.94 | TLR8 (0.70) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL3648737 | 0.87 | — | — | |
| Water SCHEMBL28334818 | 0.85 | TLR8 (0.58) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL27658200 | 0.83 | TLR8 (0.67) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL27637305 | 0.82 | TLR8 (0.70) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL27658203 | 0.82 | TLR8 (0.65) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL12802888 | 0.82 | TLR8 (0.89) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL9255222 | 0.81 | ALDH1A1 (0.47) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL5464719 | 0.80 | TLR8 (1.00) | TLR8ARG1ALDH1A1POLBKMT2A | |
| SCHEMBL27637354 | 0.80 | TLR8 (0.68) | TLR8ARG1ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037680-B | A kind of osmosis type modified aqueous polyurethane waterproofing agent | 上海东和胶粘剂有限公司 | 2017-12-26 | — | — | CN | claimed |
| CN-105037680-A | Permeable modified waterborne polyurethane waterproof agent | SHANGHAI DONGHE ADHESIVE CO LTD | 2015-11-11 | — | — | CN | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1326850-C | Tricyclic farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020103207-A1 | Farnesyl protein transferase inhibitors | TAVERAS ARTHUR G (US) | 2002-08-01 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| CN-1334811-A | Tricyclic farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2002-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | TLR8 4872/4885ARG1 2058/4885ALDH1A1 1789/4885 |
| US-20020103207-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, ACAT2 | TLR8 4535/4885ARG1 1637/4885ALDH1A1 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.